MAPT and Parkinson disease: Indeed, a recent study of 232 PD cases reporting association between APOE-ɛ4 and dementia status (OR 5.15) found Alzheimer’s type pathology including moderate to high frequency neuritic plaques and Braak tau stage ≥3 in 90% of APOE-ɛ4 carriers coming to postmortem (n = 10) compared to 43–53% of non-carriers (n = 19) (89).